Biotechs Leading the Healthcare Sector - Alliqua, Pacific Biosciences, Oncothyreon, Keryx, Organovo
CORAL SPRINGS, Florida, September 26, 2013 /PRNewswire/ --
According to the Medical Market Forecasts issued by Espicom, the global medical device, technology, and equipment market is expected to rise more than $440.5 billion by 2018. FinancialNewsMedia.com issues market news updates for today's active biotech companies: Alliqua, Inc. (OTCQB: ALQA), Pacific Biosciences of California Inc. (NASDAQ: PACB), Oncothyreon Inc. (NASDAQ: ONTY), Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) and Organovo Holdings, Inc. (NYSE: ONVO).
Alliqua, Inc. (OTCQB: ALQA) Headline: Alliqua Becomes Exclusive Distributor of Sorbion-Branded Wound Products in the Americas Through Agreement with Carolon. Alliqua, Inc. today announced the Company has entered into an agreement with Carolon Health Care Products through which it will gain both new sales distribution pathways and established customers. As previously announced, Alliqua has also entered into an agreement to become a sales and distribution agent in the Americas for Europe's wound-healing sorbion GmbH & Co. KG ("sorbion") branded product line, including sorbion's sachet S wound products that Carolon has been selling. Access to the distribution network, customers and sales force provided by the Carolon agreement will be leveraged to sell the sorbion products as well as the Company's hydrogel product line, which is sold under the SilverSeal® and Hydress® brands.
To read the entire press release, please go to http://www.fnmprofiles.com/profiles-alqa.php
Highlights For ALQA Distributorship:
• Alliqua becomes exclusive sales agent of sorbion-branded products in the Americas
• Gains access to Carolon's established distribution relationships with major wholesalers and healthcare facilities in the wound healing industry
• Obtains contract opportunities with experienced wound-sales force, thereby adding strength and reach to Alliqua's existing team
• Sales force may now also represent and sell Alliqua's 510(k) FDA-approved hydrogel products for wound care (marketed under the SilverSeal and Hydress brands) through the expanded distribution channels
• Alliqua significantly enhances potential sales footprint for future product line acquisitions and partnerships
Pacific Biosciences of California Inc. (NASDAQ: PACB), provider of the PacBio ® RS II DNA Sequencing System, announced that it has entered into an agreement with Roche Diagnostics to develop diagnostic products, including sequencing systems and consumables, based on Pacific Biosciences' Single Molecule, Real-Time (SMRT ®) technology. Pacific Biosciences will develop and manufacture certain products intended for clinical use, which it will sell exclusively to Roche. Roche obtained worldwide rights to exclusively distribute these products in the field of human in vitro diagnostics. Pacific Biosciences will continue to market its current and future products for all fields outside of human in vitro diagnostics, including research, plant, animal, and applied markets.
Oncothyreon Inc. (NASDAQ: ONTY) announced that Merck Serono, the biopharmaceutical division of Merck KGaA, has decided to continue clinical development of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25 and formerly known as Stimuvax®). Merck Serono, which is developing tecemotide under a license agreement with Oncothyreon, will conduct a new Phase 3 trial called START2 for patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) announced on Tuesday that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at BioCentury's NewsMakers in the Biotech Industry Conference at 3:00 pm EDT on Friday, September 27, 2013, in New York City. A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of this webcast will be available following the conclusion of the live presentation.
Organovo Holdings, Inc. (NYSE: ONVO) develops three-dimensional (3D) bioprinting technology for creating functional human tissues on demand for research and medical applications. The company's 3D NovoGen bioprinting technology works across various tissue and cell types, and allows for the placement of cells in desired pattern. It offers NovoGen MMX Bioprinter, a commercial hardware and software bioprinter platform to create tissues for bioprinting research and development. ONVO closed up 1.51% on Wednesday on over 3Mil shares traded.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup. Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PRESS to 545454. (SMS alerts are free, however data rates may apply, check your wireless plan for details.)
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group LLC